← Innovent Biologics overview

Innovent Biologics vs Akeso: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Innovent Biologics Inc (1801.HK)

Q3 2026
▲3▼1

Innovent advances pipeline, licensing, and revenue; risks persist

  • Pipeline and licensing progress Innovent started Phase 3 trials for a fast-tracked myeloma antibody, gained China rights to Verzenio and Vanflyta, licensed IBI355 to Spero for up to $1.1B, and filed the world's first weekly oral GLP-1.

    These pipeline and licensing moves are key new developments that can drive future growth and investor optimism.

  • Strong revenue growth First-half product revenue rose over 55% to 8.2 billion yuan, showing strong commercial execution and underlying business momentum.

    Revenue growth is a fundamental driver of stock performance and reflects the company's financial health.

  • Sector re-rating on licensing activity A sector re-rating driven by record Chinese licensing activity boosted valuations across the biotech space, lifting Innovent's shares.

    This external factor improved sentiment and valuation multiples for the entire sector, including Innovent.

  • Risks from trial and deal flow Sector rallies can cool if deal flow slows, and pipeline bets like IBI3003 and IBI3042 depend on costly, uncertain late-stage trials and regulatory outcomes.

    These risks could negatively impact the stock if they materialize, providing a balanced view.

August 2026
▲4

Innovent adds Daiichi deal and weekly GLP-1 filing as sector re-rates

  • World-first weekly oral GLP-1 enters clinic Innovent's IBI3042 became the first small-molecule weekly oral GLP-1 to reach clinical stage, with China's drug regulator accepting the filing. A once-weekly pill would be easier for patients than injections, so success could open a large obesity and diabetes market and lift long-term sales hopes.

    New pipeline milestone that expands Innovent's biggest growth opportunity beyond current products.

  • Wins China rights to Daiichi Sankyo's Vanflyta Innovent secured exclusive China commercialization rights for Vanflyta, a leukemia drug approved in June 2026, while Daiichi Sankyo handles development and supply. This adds a near-term oncology product to sell through Innovent's existing hospital network, lifting revenue without big new research spending.

    A concrete new commercial deal that adds revenue and shows Innovent's partnering strength.

  • First-half product revenue up over 55% Innovent's first-half product revenue topped 8.2 billion yuan, up more than 55% year on year, reported alongside strong results from BeiGene and RemeGen. Faster product sales show its medicines are being adopted widely, which supports profit growth and gives the stock a fundamental reason to rise.

    Actual reported sales growth is the core evidence behind the share price move.

  • Sector re-rating on record licensing and Moderna data Chinese drug licensing deals hit about $99.7 billion in the first half, roughly double all of 2024, and Moderna's cancer vaccine success lifted biotech shares globally. Innovent landed billion-dollar overseas deals, so investors are paying more for its pipeline. Counterweight: sector rallies can cool if deal flow slows.

    Explains the broad demand backdrop pushing innovative drug stocks, including Innovent, higher.

Latest
▲4

Innovent adds Daiichi deal and weekly GLP-1 filing as sector re-rates

  • World-first weekly oral GLP-1 enters clinic Innovent's IBI3042 became the first small-molecule weekly oral GLP-1 to reach clinical stage, with China's drug regulator accepting the filing. A once-weekly pill would be easier for patients than injections, so success could open a large obesity and diabetes market and lift long-term sales hopes.

    New pipeline milestone that expands Innovent's biggest growth opportunity beyond current products.

  • Wins China rights to Daiichi Sankyo's Vanflyta Innovent secured exclusive China commercialization rights for Vanflyta, a leukemia drug approved in June 2026, while Daiichi Sankyo handles development and supply. This adds a near-term oncology product to sell through Innovent's existing hospital network, lifting revenue without big new research spending.

    A concrete new commercial deal that adds revenue and shows Innovent's partnering strength.

  • First-half product revenue up over 55% Innovent's first-half product revenue topped 8.2 billion yuan, up more than 55% year on year, reported alongside strong results from BeiGene and RemeGen. Faster product sales show its medicines are being adopted widely, which supports profit growth and gives the stock a fundamental reason to rise.

    Actual reported sales growth is the core evidence behind the share price move.

  • Sector re-rating on record licensing and Moderna data Chinese drug licensing deals hit about $99.7 billion in the first half, roughly double all of 2024, and Moderna's cancer vaccine success lifted biotech shares globally. Innovent landed billion-dollar overseas deals, so investors are paying more for its pipeline. Counterweight: sector rallies can cool if deal flow slows.

    Explains the broad demand backdrop pushing innovative drug stocks, including Innovent, higher.

July 2026
▲4

Innovent advances novel drugs and expands commercial reach

  • Tri-specific antibody enters Phase 3 Innovent dosed the first patient in a Phase 3 trial of IBI3003 for multiple myeloma. This novel therapy showed strong early results and has FDA Fast Track status. Success could add a major new treatment to Innovent's pipeline, boosting future revenue prospects.

    This is a new clinical milestone that could lead to a new drug approval and revenue stream.

  • Ollin raises $330M for eye drug Innovent's partner Ollin Biosciences raised $330 million to fund global Phase 3 trials of an eye drug discovered by Innovent. The trials will include China and South Korea. This validates Innovent's research and could bring milestone payments and royalties.

    This is new partnership progress that could generate future revenue for Innovent.

  • Gains China rights to Verzenio Eli Lilly handed over sole commercialization rights for breast cancer drug Verzenio in mainland China to Innovent. The drug had about $221 million in sales last year. This expands Innovent's oncology portfolio and adds immediate revenue.

    This is a new commercial agreement that directly boosts Innovent's product sales.

  • Licenses anti-CD40L antibody to Spero Innovent licensed IBI355, an autoimmune disease antibody, to Spero Therapeutics outside Greater China in a deal worth up to $1.1 billion. Innovent gets an upfront payment and potential milestones and royalties, while keeping China rights.

    This is a new out-licensing deal that provides cash and validates Innovent's pipeline.

▲4

Innovent advances novel drugs and expands commercial reach

  • Tri-specific antibody enters Phase 3 Innovent dosed the first patient in a Phase 3 trial of IBI3003 for multiple myeloma. This novel therapy showed strong early results and has FDA Fast Track status. Success could add a major new treatment to Innovent's pipeline, boosting future revenue prospects.

    This is a new clinical milestone that could lead to a new drug approval and revenue stream.

  • Ollin raises $330M for eye drug Innovent's partner Ollin Biosciences raised $330 million to fund global Phase 3 trials of an eye drug discovered by Innovent. The trials will include China and South Korea. This validates Innovent's research and could bring milestone payments and royalties.

    This is new partnership progress that could generate future revenue for Innovent.

  • Gains China rights to Verzenio Eli Lilly handed over sole commercialization rights for breast cancer drug Verzenio in mainland China to Innovent. The drug had about $221 million in sales last year. This expands Innovent's oncology portfolio and adds immediate revenue.

    This is a new commercial agreement that directly boosts Innovent's product sales.

  • Licenses anti-CD40L antibody to Spero Innovent licensed IBI355, an autoimmune disease antibody, to Spero Therapeutics outside Greater China in a deal worth up to $1.1 billion. Innovent gets an upfront payment and potential milestones and royalties, while keeping China rights.

    This is a new out-licensing deal that provides cash and validates Innovent's pipeline.

Akeso Inc (9926.HK)

Q3 2026
▲3▼1

Ivonescimab's Phase 3 Win and FDA Path Drive Akeso Higher

  • Ivonescimab's Phase 3 Win and Third China Approval Ivonescimab beat Keytruda in a Phase 3 trial, cutting death risk 27%, and won a third China lung-cancer approval. This validates the drug's potential and boosts investor confidence.

    This is the major clinical and regulatory success that drove positive sentiment.

  • AstraZeneca's $2B Investment in Summit AstraZeneca's $2B investment in partner Summit Therapeutics signals strong external confidence in ivonescimab and provides resources for global development, lifting Akeso's shares.

    This partnership news directly boosted investor confidence and provided validation.

  • Pipeline Expansion and Sector Momentum New ADC and cadonilimab trials expanded the pipeline, while record Chinese presence at ESMO and sector momentum added to positive sentiment, supporting the stock.

    These developments show progress and broader industry support, contributing to the stock's rise.

  • Clinical and Regulatory Risks Ivonescimab's benefit was weaker and not statistically reliable in lower-PD-L1 patients, most pipeline programs are years from revenue, and US market access is still draft-stage, posing risks.

    These are the key counterweights that could limit upside and create uncertainty.

September 2026
▲3

Akeso's ivonescimab bests Keytruda; pipeline and partner investment lift outlook

  • Ivonescimab beats Keytruda in Phase 3 lung cancer trial Akeso's ivonescimab cut the risk of death by 27% versus Keytruda in a Phase 3 lung-cancer trial, with a 42% reduction in high-PD-L1 patients. This strong data boosts confidence in the drug's competitiveness.

    This is the major new clinical catalyst that directly supports the stock's potential.

  • AstraZeneca's $2B investment in Summit lifts Akeso AstraZeneca invested $2 billion in Summit Therapeutics, Akeso's partner for ivonescimab. This boosts confidence in the drug's global potential and could accelerate US licensing and development.

    This new partnership validates the drug and improves Akeso's royalty prospects.

  • Two new ADCs enter Phase 1; cadonilimab advances Akeso started Phase 1 trials for two new antibody-drug conjugates (ADCs) and advanced cadonilimab into global and new-indication trials. These early-stage programs add to the pipeline but are years from revenue.

    Shows pipeline progress but also highlights that most revenue is still far off.

  • Weaker lower-PD-L1 benefit and early-stage pipeline temper optimism Ivonescimab's benefit was weaker and not statistically reliable in lower-PD-L1 patients, and most pipeline programs are early-stage. US policy access remains draft-stage, leaving regulatory risk.

    Provides a balanced view of the risks that could limit upside.

Latest
▲4

Akeso's pipeline expands as U.S. opens door to Chinese drug deals

  • U.S. rules may let Chinese drug licensing deals go ahead Washington is drafting rules that would likely allow U.S. drugmakers to license medicines from Chinese biotechs, excluding weaponizable biotech. Akeso shares jumped 8% on the news. If it holds, Akeso keeps access to the big, high-priced U.S. market — the main reason its pipeline is worth so much.

    This is the single biggest new force on Akeso's price: it protects the overseas licensing route that underpins its valuation.

  • AstraZeneca puts $2B into Summit and will test ivonescimab combos AstraZeneca will invest $2 billion in Summit, Akeso's overseas partner, and lead trials combining Akeso's ivonescimab with its own cancer drugs in gut tumors. A global pharma giant funding and running studies raises confidence in ivonescimab's overseas path and cuts Akeso's own development risk.

    A major partner's money and trial backing directly strengthens the case for Akeso's flagship drug abroad.

  • Cadonilimab moves into global and new-indication trials Akeso started a global Phase III gastric-cancer trial for cadonilimab and dosed the first patient in a Phase III colon-cancer study, where earlier data showed an 84.6% complete response. Each new indication widens the drug's future sales base, though revenue is still years away.

    These trials expand the long-term sales potential of Akeso's second big drug beyond its current approved uses.

  • Ivonescimab data and new combo trial keep pipeline momentum Positive survival data for ivonescimab in biliary tract cancer was picked for ESMO's top session, with about 30 bispecific studies to be presented. A Phase II breast-cancer trial combining a new ADC with ivonescimab also began. More proof points support the drug's breadth, but they are early-stage.

    It shows the flagship drug and pipeline are still producing data that can support future approvals and sales.

▲4

Akeso's lung-cancer drug beats Keytruda on survival; two new ADCs enter clinic

  • Ivonescimab beats Keytruda on overall survival Akeso's ivonescimab cut the risk of death by 27% versus Merck's Keytruda in a China Phase 3 lung-cancer trial, with patients living a median 30.8 months versus 22.6. This is the strongest proof yet that Akeso's flagship drug may be better than the world's best-selling cancer drug, lifting its long-term sales outlook.

    The survival win is the period's biggest value driver for 9926.HK.

  • Benefit strongest in high PD-L1 patients In patients whose tumors had high PD-L1 levels, ivonescimab cut death risk by 42%. In lower-PD-L1 patients the benefit was smaller and not statistically reliable. So the drug's edge is real but narrower than headlines suggest, which tempers how much extra sales investors should assume.

    It is the honest counterweight inside the same trial result.

  • Global confirmatory trial and FDA decision ahead Summit is recruiting 780 patients for HARMONi-7, a global trial testing ivonescimab against Keytruda, and the FDA is reviewing a separate application in previously treated EGFR-mutated lung cancer with a November 14 decision date. Success would open the much larger U.S. and European markets.

    It shows the path from China approval to global revenue.

  • Two new ADCs cleared for human testing China's drug regulator cleared Phase 1 trials for AK157D1, a B7-H3 ADC, and AK158D1, a bispecific EGFR/TROP2 ADC. These are Akeso's third and fourth ADCs to reach the clinic, showing a deep pipeline beyond ivonescimab, though any revenue is years away.

    Pipeline breadth supports the long-term growth story.

August 2026
▲4

Akeso's ivonescimab wins third China lung-cancer approval; pipeline advances

  • New China approval for ivonescimab in squamous lung cancer China's drug regulator approved ivonescimab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer — the drug's third approved lung-cancer use. More approved uses mean more patients can be treated, supporting future sales and royalties for Akeso.

    This is the period's biggest company-specific event and directly expands the commercial market for Akeso's lead drug.

  • Ivonescimab's US review and survival data stay on track Partner Summit Therapeutics said the FDA decision on ivonescimab for EGFR-mutant lung cancer is expected by November 14, 2026, and updated survival data showed a consistent benefit across Western and Asian patients. A US approval would open a far larger market and lift Akeso's royalty stream.

    It shows the main global catalyst for Akeso's lead drug is still progressing, which underpins the stock's long-term value.

  • Pipeline push: bispecific ADC combined with ivonescimab Akeso began a Phase II trial of its bispecific ADC AK146D1 combined with ivonescimab in advanced lung cancer, and started a similar breast-cancer study. Early-stage trials are years from sales, but they show the pipeline can produce future growth beyond today's approved drugs.

    It answers what is driving the longer-term story: new pipeline assets that could become future revenue.

  • Sector-wide rally and record China presence at ESMO Chinese drugmakers' oral presentations at ESMO 2026 hit a record 47, with Akeso named a leader, and a broad pharma rally followed strong earnings from WuXi AppTec, BeiGene and Innovent. A rising sector tide can lift Akeso shares even without company-specific news.

    It explains the market backdrop pushing the whole sector, including Akeso, higher this period.

▲4

Akeso's ivonescimab wins third China lung-cancer approval; pipeline advances

  • New China approval for ivonescimab in squamous lung cancer China's drug regulator approved ivonescimab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer — the drug's third approved lung-cancer use. More approved uses mean more patients can be treated, supporting future sales and royalties for Akeso.

    This is the period's biggest company-specific event and directly expands the commercial market for Akeso's lead drug.

  • Ivonescimab's US review and survival data stay on track Partner Summit Therapeutics said the FDA decision on ivonescimab for EGFR-mutant lung cancer is expected by November 14, 2026, and updated survival data showed a consistent benefit across Western and Asian patients. A US approval would open a far larger market and lift Akeso's royalty stream.

    It shows the main global catalyst for Akeso's lead drug is still progressing, which underpins the stock's long-term value.

  • Pipeline push: bispecific ADC combined with ivonescimab Akeso began a Phase II trial of its bispecific ADC AK146D1 combined with ivonescimab in advanced lung cancer, and started a similar breast-cancer study. Early-stage trials are years from sales, but they show the pipeline can produce future growth beyond today's approved drugs.

    It answers what is driving the longer-term story: new pipeline assets that could become future revenue.

  • Sector-wide rally and record China presence at ESMO Chinese drugmakers' oral presentations at ESMO 2026 hit a record 47, with Akeso named a leader, and a broad pharma rally followed strong earnings from WuXi AppTec, BeiGene and Innovent. A rising sector tide can lift Akeso shares even without company-specific news.

    It explains the market backdrop pushing the whole sector, including Akeso, higher this period.